Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

IMPAVIDO

MILTEFOSINE

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview IMPAVIDO is listed in Drugs@FDA under application 204684 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient MILTEFOSINE Form and strength CAPSULE;ORAL - 50MG Sponsor KNIGHT THERAPS Submission history Latest submission status date: 2025-03-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMPAVIDO is listed in Drugs@FDA under application 204684 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient MILTEFOSINE Form and strength CAPSULE;ORAL - 50MG Sponsor KNIGHT THERAPS Submission history Latest submission status date: 2025-03-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.